Independent, peer-reviewed clinical trials.
Peer-reviewed, placebo-controlled, published. The evidence behind every AYA BIOME™® formula.
Body Composition & Liver Function
Participants received 500mg fermented turmeric daily for 8 weeks. All outcomes measured against placebo group. Statistical significance threshold: p < 0.05.
0
% Body Fat
vs. placebo · p = 0.007
0
% ALT Liver Enzyme
vs. placebo · p = 0.009
0
% γ-GTP
Liver stress marker · p = 0.014
0
% Waist Circumference
vs. placebo · p = 0.012
Gut Health, Inflammation & Oxidative Stress
Participants received 500mg fermented turmeric daily for 12 weeks. Primary endpoints: inflammatory markers, gut microbiome composition, oxidative stress.
0
% hs-CRP Inflammation
C-reactive protein · p < 0.05
0
% Butyrate Production
Short-chain fatty acids
0
% SOD Oxidative Stress
Superoxide dismutase activity
0
% Microbiome Diversity
Shannon diversity index
Menopause, Skin & Cardiovascular Health
S-equol is a postbiotic metabolite produced from soy isoflavones by gut bacteria - but only 20-30% of Western women can make it. Women's Wellness delivers it directly. Aso et al. (2012) in the Journal of Women's Health randomised 126 non-equol-producing postmenopausal women to 10mg S-equol daily for 12 weeks, recording a 58.7% reduction in hot flush frequency vs. 34.5% in the placebo group (p=0.009). A parallel mood trial documented significant improvements in depression, tension, and fatigue scores. Oyama et al. (2012) in Menopause showed significant reductions in crow's-feet wrinkle area at both 10mg and 30mg doses (p<0.05). Further trials documented LDL reduction (p<0.01), arterial stiffness improvement, and bone mineral density preservation (p=0.027).
0
Hot Flush Frequency
Aso et al. 2012 · vs. placebo · p = 0.009
0
Triglycerides
cardiovascular trial · vs. placebo
0
Parathyroid Hormone
elevated PTH levels · vs. placebo
0
Daily Dose
clinical benchmark · all published RCTs
Blood Pressure & Coagulation Factors
Nattokinase is a fibrinolytic enzyme produced during soybean fermentation, studied for cardiovascular and coagulation effects in peer-reviewed human trials. Kim et al. (2008) in Hypertension Research randomised 86 participants with untreated elevated blood pressure to 2,000 FU nattokinase or placebo for 8 weeks. Both systolic and diastolic blood pressure fell significantly vs. placebo, with renin activity also reduced - suggesting an ACE-inhibitory mechanism. Hsia et al. (2009) in Nutrition Research enrolled 45 participants across healthy, cardiovascular risk, and dialysis groups receiving 2,000 FU nattokinase daily for two months, recording significant reductions in fibrinogen, factor VII, and factor VIII - three independent risk factors for thrombotic events.
-5.55mmHg
Systolic Blood Pressure
Kim et al. 2008 · vs. placebo · p < 0.05
-2.84mmHg
Diastolic Blood Pressure
vs. placebo · p < 0.05
0
Factor VIII
Hsia et al. 2009 · p < 0.001
0
Factor VII
coagulation factor · p < 0.001
Gold-standard research design.
Randomised & Controlled
Participants were randomly assigned. Neither group knew who received what.
Statistically Significant
All highlighted results met the p < 0.05 threshold for statistical significance.
Ethics Approved
All human trials reviewed and approved by independent ethics boards.
Third-Party Verified
Studies conducted at independent research facilities, not in-house.
About the evidence.
All trials follow the gold standard: randomised, double-blind, placebo-controlled. Participants were randomly assigned to treatment or placebo groups. Neither participants nor researchers knew who received what. This eliminates bias and confirms that observed benefits come from the formula, not chance.
The 8-week trial showed significant body composition and liver improvements. The 12-week trial demonstrated substantial inflammatory and microbiome changes. For meaningful outcomes, we recommend consistent daily use for at least 8 weeks before assessing results.
These studies report average outcomes across all participants in the treatment group. Individual results vary based on baseline health, diet, lifestyle, and genetics. The statistically significant results indicate that the majority of participants experienced measurable improvements compared to placebo.
Across all human trials, no serious adverse events were reported. The formula was well-tolerated by all participants, with compliance rates exceeding expectations.
Yes. Full study reports are available on request. Contact us via the link below and our research team will send complete documentation.